CELL INTELLIGENCE · 肿瘤细胞治疗研究

胶质母细胞瘤中的信号通路失调与治疗耐药：分子机制与新兴治疗靶点

Pathway dysregulation and therapeutic resistance in glioblastoma: molecular mechanisms and emerging therapeutic targets.

儿童脑肿瘤的局部区域和全身过继性细胞疗法：CAR-T、TCR 工程 T 细胞和 NK 细胞策略的系统综述

Locoregional and systemic adoptive cellular therapies for pediatric brain tumors: a systematic review of CAR‑T, TCR‑engineered T cells, and NK cell st

CAR-NK 细胞中 IL-10 的耗竭增强肿瘤微环境的重编程并改善治疗效果

Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy.

使用第二近红外共轭寡电解质探针的过继免疫细胞分布与扩增超灵敏体内成像

Ultrasensitive In Vivo Imaging of Adoptive Immune Cell Distribution and Expansion Using Second Near-Infrared Conjugated Oligoelectrolyte Probes.

ROBO1 CAR-NK92 细胞中 Cbl-b 敲除增强其抗肿瘤疗效

Ablation of Cbl-b in ROBO1 CAR-NK92 Cells Enhances Their Antitumor Efficacy.

胶质母细胞瘤的下一代 CAR-NK 细胞治疗：克服抗原逃逸与免疫抑制性肿瘤微环境的策略

Next-generation CAR-NK cell therapy for glioblastoma: strategies to overcome antigen escape and the immunosuppressive tumor microenvironment.

Dual-target CAR-NK（NK 细胞）治疗胶质瘤、胶质母细胞瘤：I 期临床试验

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

这是一项 I 期、非随机的注册临床试验，评估 NK 细胞治疗胶质瘤、胶质母细胞瘤的疗效与安全性。研究设计：非随机、3 个分组。当前状态：招募中。计划入组 36 例。试验地点：中国 · 深圳（共 1 个中心，其中中国 1 个）。登记号：NCT07551336。

靶向 COX-2/PGE(2) 轴增强脑肿瘤中 NK 和 T 细胞免疫治疗

Targeting the COX-2/PGE(2) axis to enhance NK and T cell immunotherapy in brain tumors.

开发基于溶瘤病毒递送 CD19 和 EGFRvIII 抗原与双特异性 CAR 的胶质母细胞瘤多模式治疗

Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs.

靶向 PSMD14-BCKDK 通路克服免疫抑制并增强 CAR-NK 在胶质母细胞瘤中的浸润

Targeting the PSMD14-BCKDK pathway overcomes immune suppression and enhances CAR-NK infiltration in glioblastoma.